by B2i | Sep 25, 2023 | Press Releases
Company remains on track to initiate the clinical trial in Q4 of 2023 ROCKVILLE, Md., Sept. 25, 2023 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of...
by B2i | Sep 13, 2023 | Press Releases
ROCKVILLE, Md., Sept. 13, 2023 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT), today announced...
by B2i | Sep 11, 2023 | Press Releases
ROCKVILLE, Md., Sept. 11, 2023 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT), today announced...
by B2i | Aug 29, 2023 | Press Releases
ROCKVILLE, Md., Aug. 29, 2023 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT), today announced...
by B2i | Aug 15, 2023 | Press Releases
ROCKVILLE, Md., Aug. 15, 2023 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today provided a...
